Cerebellar granule neurons are the most abundant neurons in the brain, and a critical element of the circuitry that controls motor coordination and learning. In addition, granule neuron precursors (GNPs) are thought to represent cells of origin for medulloblastoma, the most common malignant brain tumor in children. Thus, understanding the signals that control the growth and differentiation of these cells has important implications for neurobiology and neurooncology. Our previous studies have shown that proliferation of GNPs is regulated by Sonic hedgehog (Shh), and that aberrant activation of the Shh pathway can lead to medulloblastoma. Moreover, we have demonstrated that Shh-dependent proliferation of GNPs and medulloblastoma cells can be blocked by basic fibroblast growth factor (bFGF). But while the mitogenic effects of Shh signaling have been confirmed in vivo, the inhibitory effects of bFGF have primarily been studied in culture. Here, we demonstrate that mice lacking FGF signaling in GNPs exhibit no discernable changes in GNP proliferation or differentiation. In contrast, activation of FGF signaling has a potent effect on tumor growth: treatment of medulloblastoma cells with bFGF prevents them from forming tumors following transplantation, and inoculation of tumor-bearing mice with bFGF markedly inhibits tumor growth in vivo. These results suggest that activators of FGF signaling may be useful for targeting medulloblastoma and other Shh-dependent tumors.
INTRODUCTION
Normal development requires a delicate balance between proliferation and differentiation. Too little proliferation can result in impaired tissue structure and function, whereas excessive proliferation can lead to cancer. One salient example of this is the development of granule neurons in the cerebellum. Mutant mice that fail to generate enough granule cells develop severe ataxia, [1] [2] [3] and patients with congenital granule cell degeneration have deficits in motor coordination, language use and cognitive function. 4 Conversely, when granule neuron precursor (GNP) differentiation fails, cells that would normally become postmitotic continue to proliferate and give rise to medulloblastoma. 5, 6 Thus, elucidating the molecular mechanisms that control growth and differentiation of granule neurons is critical for understanding both normal cerebellar development and tumorigenesis.
GNPs are generated on the surface of the cerebellum in a structure called the external germinal layer (EGL). 7, 8 At birth, the EGL contains a single layer of undifferentiated cells, but over the next few days, these cells undergo extensive proliferation to generate a large pool of GNPs. 9, 10 As new GNPs are generated, older cells exit the cell cycle and differentiate, and their cell bodies migrate inward to the internal granule layer. 11, 12 The waves of proliferation and differentiation continue until about 3 weeks of age (in mice), when all GNPs mature into granule neurons and the EGL disappears. 13 Studies from our lab and others have demonstrated that the major mitogen for GNPs is Sonic hedgehog (Shh). [14] [15] [16] Produced by Purkinje neurons, Shh acts by binding to the transmembrane protein Patched (Ptc). In the absence of Shh, Ptc acts as an antagonist of the hedgehog pathway, inhibiting the function of the signal transducing protein Smoothened (Smo). When Shh binds to Ptc, inhibition is alleviated, and Smo initiates a signaling cascade that results in activation of Gli family transcription factors and expression of hedgehog target genes. 17, 18 In GNPs, these include N-myc and cyclins D1 and D2, 19, 20 and thus Shh signaling results in a robust proliferative response. Notably, mice with targeted mutations that impair Shh signaling (for example, deletion of Shh, Smo or Gli2) exhibit decreased GNP proliferation; [21] [22] [23] conversely, animals with mutations that activate the pathway (for example, deletion of ptc) develop medulloblastoma. 5, 6, [24] [25] [26] The fact that B30% of human medulloblastomas contain activating mutations in the Shh pathway [27] [28] [29] also implies a key role for this pathway in proliferation and tumorigenesis.
However, although the importance of Shh in GNP proliferation is well established, the signals that cause GNPs to exit the cell cycle and differentiate remain much less clear. One potential explanation might be decreased exposure of GNPs to Shh ligand. However, previous studies have shown that Shh continues to be expressed by Purkinje cells into adulthood. 30 The fact that GNPs can exit the cell cycle despite the continued presence of Shh suggests that some other signal may override the mitogenic effects of Shh. We have previously shown that bFGF can block proliferation and promote differentiation of GNPs in the presence of Shh, 14, 31 raising the possibility that FGFs might serve as differentiation factors for these cells. In addition, we have shown that bFGF can inhibit the growth of tumor cells from ptc mutant mice, 31 suggesting that this pathway may hold promise for medulloblastoma therapy.
Although FGFs have been shown to inhibit proliferation of GNPs and tumor cells in vitro, their effects on these cells have not been rigorously tested in vivo. In the current study, we used conditional knockout mice to investigate the importance of FGF signaling in GNP development in vivo, and intratumoral injections to test the efficacy of bFGF as a treatment for medulloblastoma. Our results suggest that genetic ablation of FGFRs does not alter GNP differentiation in vivo. However, exposure of medulloblastoma cells to bFGF dramatically inhibits their growth. Thus, although bFGF may not be critical for GNP development, activation of the FGF pathway may be useful in the treatment of Shh-dependent tumors.
RESULTS AND DISCUSSION
FGF inhibits proliferation of GNPs during postnatal development GNPs undergo proliferation and differentiation in the EGL during the first 2-3 weeks after birth. Our previous studies 31 have shown that bFGF inhibits proliferation and promotes differentiation of GNPs. To determine whether the inhibitory effects of bFGF are age-dependent, we isolated GNPs at a range of postnatal ages and measured incorporation of tritiated thymidine in response to Shh and bFGF. Consistent with our previous observations, P7 GNPs proliferated robustly in response to Shh, and this response was abolished by addition of bFGF (Figure 1c ). Marked inhibition of Shh-induced proliferation was also seen at P2, P4 and P11 (Figures 1a, b and d) . Thus, bFGF can inhibit proliferation of GNPs throughout postnatal development. bFGF promotes cell cycle exit and acts downstream of suppressor of fused Our previous studies suggested that bFGF promotes cell cycle exit of GNPs and accelerates their differentiation into granule neurons. 31 To better understand the mechanisms by which bFGF inhibits proliferation, we performed cell cycle analysis on cells treated with Shh±bFGF. As shown in Supplementary Figures 1A-C, in the absence of growth factors the majority of GNPs exit the cell cycle within 48 h (o 2% of cells in S, G 2 and M phases of the cell cycle). Treatment with Shh maintains a population of GNPs in cycle (B11% of cells in S/G 2 /M). However, co-treatment with bFGF inhibits the effects of Shh and causes cells to accumulate in the G 0 /G 1 phase of the cell cycle (B2% of cells in S/G 2 /M). We also examined whether bFGF increased apoptosis by staining cells with antibodies specific for cleaved caspase 3. As shown in Supplementary Figure 2A , bFGF did not cause a significant increase in apoptosis. Together, these data suggest that bFGF acts by promoting cell cycle exit and differentiation rather than by inducing cell death.
We previously showed that bFGF can inhibit proliferation of GNPs in response to stimulation with Shh ligand, as well as of tumor cells resulting from mutations in ptc. 31 These data suggest that bFGF acts on the Shh pathway at a level downstream of ptc. To gain further insight into the mechanisms by which bFGF interferes with Shh signaling, we tested the effects of bFGF on cells in which the Shh pathway is activated as a consequence of a Smo mutation. NeuroD2-SmoA1 transgenic mice exhibit increased Shh pathway activation and proliferation of GNPs and develop medulloblastoma. 32 As shown in Supplementary Figure 3A , we found that bFGF inhibits the basal proliferation of these cells, suggesting that it acts downstream of Smo.
Shh target genes can also be activated by mutations in Suppressor of Fused (Sufu), a negative regulator of the pathway that regulates processing, localization and transcriptional activity of Gli proteins. [33] [34] [35] To determine whether bFGF could suppress activation of the pathway resulting from loss of Sufu, we tested the effects of bFGF on mouse embryo fibroblasts (MEFs) from Sufu-deficient mice. 36 As shown in Supplementary Figure 3B , Sufu À / À MEFs exhibit constitutive expression of gli1 that is significantly higher than that seen in wild-type (WT) MEFs. Importantly, addition of bFGF to Sufu À / À MEFs results in a threefold reduction in gli1 expression, suggesting that bFGF can inhibit activation of the pathway mediated by loss of Sufu. Similar results were observed when a Gli-luciferase reporter gene was used to monitor gli1 expression (data not shown). Together these Figure 1 . bFGF inhibits proliferation of GNPs throughout postnatal development. GNPs were isolated from P2 (a), P4 (b), P7 (c) or P11 (d) mice and cultured in media with no added factors (control) or 20% Shh supernatant ± bFGF (25 ng/ml) for 48 h. Cells were pulsed with tritiated thymidine ( 3 H-Td) and cultured for 16 h before being assayed for thymidine incorporation. Data represent means of triplicate samples ± s.e.m. Differences in proliferation between Shh and Shh þ bFGF were statistically significant (Po0.0001 based on Student's t-test) at P4, P7 and P11; at P2, the difference was 2.7-fold, but did not reach significance (P ¼ 0.09). data suggest that bFGF inhibits Shh signaling at a level downstream of Smo and Sufu, and proximal to the nucleus.
The inhibitory effects of bFGF are mediated by FGFR1 The FGF receptor family consists of four members (FGFR1-4), three of which can undergo alternative splicing to generate multiple receptor isoforms (FGFR4 exists in only one isoform). 37 To determine which receptors might mediate inhibition of Shh signaling and proliferation, we first examined the receptors expressed by GNPs. Cells were FACS (fluorescence-activated cell sorting) sorted from the cerebellum of Math1-GFP transgenic mice (which express green fluorescent protein (GFP) in their GNPs 38, 39 ), and RNA was isolated and subjected to RT-PCR using primers for FGFR receptor isoforms. Consistent with previous studies, 40 we found that GNPs express FGFR1, 2 and 4; FGFR3 was also detected in some samples, but usually at lower levels than the other receptors ( Figure 2a) .
We have previously shown that FGF-mediated inhibition of Shh signaling can be blocked by pharmacological antagonists of FGFR kinase activity. 31 Because these antagonists can act on all FGF receptors, the particular receptor or receptors required for inhibition of hedgehog signaling remained unclear. To determine which FGFRs were required for the inhibitory effects of bFGF in GNPs, we used mice lacking FGFR1, 2 and 4, the predominant FGFRs expressed in these cells. Complete loss of FGFR1 or FGFR2 results in embryonic lethality;
41,42 therefore we crossed mice carrying loxP-flanked alleles of these genes 43, 44 with Math1-Cre transgenic mice 5, 6 to generate animals lacking FGFR1 or FGFR2 in GNPs. These animals, along with germline FGFR4 knockout mice (which remain viable into adulthood 45, 46 ), were used to examine the effects of loss of FGFRs on GNP responses to Shh and bFGF. GNPs from single knockout mice were cultured in the presence of Shh±bFGF for 48 h and then assayed for incorporation of tritiated thymidine. As shown in Our previous studies 31 demonstrated that FGF-mediated inhibition of Shh signaling is mediated, at least in part, by activation of the extracellular signal-regulated kinase (ERK). To determine whether GNPs lacking FGFR1 were still capable of activating this kinase, we stimulated cells with bFGF and examined the phosphorylation status of ERK. As shown in Supplementary Figure 5 , WT GNPs exhibited robust ERK phosphorylation in response to bFGF. In contrast, GNPs from mice lacking FGFR1 showed no increase in ERK phosphorylation. These studies suggest that loss of FGFR1 renders GNPs unresponsive to bFGF. FGF signaling is not required for GNP differentiation As our studies indicated that FGFR1 was a key mediator of FGFmediated inhibition in vitro, we next examined the effects of loss of FGFR1 on GNP differentiation in vivo. We isolated cerebella from WT and FGFR1-deficient mice at P7 and stained them with antibodies specific for markers of proliferation and differentiation. As shown in Figure 3a , WT cerebella contained a broad band of proliferating (Ki67 þ ) cells in the outer EGL and discrete regions of differentiating (NeuN þ ) granule neurons in the inner EGL and internal granule layer. Surprisingly, expression of Ki67 and NeuN in FGFR1 knockout mice was indistinguishable from that seen in WT littermates (Figure 3b ). These results suggested that loss of FGFR1 does not impair GNP cell cycle exit or differentiation.
One possible explanation for the lack of an in vivo phenotype in FGFR1-deficient mice was compensation by other FGFR receptors. To address this possibility, we generated triple knockout (TKO) mice lacking FGFRs 1, 2 and 4 in GNPs. Similar to GNPs from FGFR1 knockout mice, Shh-induced proliferation of GNPs from TKO mice was not inhibited by bFGF in culture (Supplementary Figure 6) , nor did TKO GNPs treated with bFGF exhibit an increase in apoptosis (Supplementary Figure 2B) . In contrast, bone morphogenetic protein 2, which inhibits GNP proliferation through a distinct mechanism, 47, 48 ) remained capable of inhibiting Shh-induced proliferation of TKO GNPs (Supplementary Figure 6) . However, analysis of TKO cerebella showed no significant differences in proliferation or differentiation when compared with WT littermates (Figures 3c-d) . Similar results were seen when cerebella were analyzed at P2, P4, P11 and P14 (data not shown). Based on these findings we conclude that FGF signaling, although capable of promoting differentiation in vitro, is not required for GNP differentiation in vivo.
FGF inhibits growth of medulloblastoma cells in vitro and in vivo
Although the above experiments suggest that FGF signaling is not essential for GNP development, they leave open the possibility that it might be useful as a treatment for Shh-dependent tumors. Recent studies from our lab have indicated that tumors from ptc þ / À -mutant mice are propagated by a subpopulation of tumor cells that expresses the carbohydrate antigen CD15/SSEA-1. 49 To determine whether CD15 þ cells are sensitive to FGF-mediated inhibition, we purified these cells by flow cytometry, cultured them in the presence or absence of bFGF, and then measured their incorporation of tritiated thymidine. As shown in Figure 4a , bFGF markedly inhibited the growth of both unfractionated and CD15 þ tumor cells. The basal proliferation of CD15-cells was much lower than their CD15 counterparts, but these cells were inhibited by bFGF as well. Moreover, we did not see an increase in apoptosis when unsorted tumor cells from ptc þ / À mice were cultured in the presence of bFGF, indicating that the reduced proliferation observed following bFGF treatment was not due to increased cell death (Supplementary Figure 7) . These results indicated that tumor-propagating cells from ptc þ / À mice are sensitive to the inhibitory effects of bFGF.
Although bFGF inhibited the growth of tumor cells, it was possible that this inhibition was transient, or that a subpopulation of tumor cells remained capable of forming tumors even after exposure to bFGF. To test this possibility, we isolated tumor cells from ptc þ / À mice and cultured them in the presence or absence of bFGF for 24 h. Cells were then transplanted into the cerebellum of SCID-beige mice and recipients were monitored for symptoms of tumor development ( Figure 4b ). As shown in Figure 4c , 93% of mice that received tumor cells cultured in control media went on to form tumors. In contrast, no tumors resulted from transplantation of FGF-treated cells. These studies demonstrated that the growth-inhibitory effects of bFGF are not transient, but rather, result in a long-lasting inability of cells to form tumors in vivo. Having shown that bFGF pretreatment could abolish the tumorigenic potential of ptc þ / À medulloblastoma cells, we wondered whether bFGF could also inhibit the expansion of tumor cells that were already growing in animals. To test this, we transplanted tumor cells into the cerebellum of SCID-beige mice, and after 8-12 days, injected phosphate-buffered saline (PBS) (vehicle) or bFGF into the implantation site. Animals received an additional injection 3-5 days later, and were then monitored for signs of tumor development (Figure 5a ). For these experiments, we used tumors from Math1-GFP;ptc þ / À mice, which allowed us to detect tumor bulk based on GFP expression. 50 As shown in Figure 5b , tumors injected with PBS typically grew unchecked, encompassing a large portion of the cerebellum. In contrast, bFGF-treated tumors were barely detectable in intact cerebella (Figure 5c ). Analysis of cerebellar sections revealed large numbers of GFP þ cells in PBS-treated animals, and few such cells in animals treated with bFGF (Figures 5d-g ). Hematoxylin and eosin staining confirmed that the area of each tumor was comparable to the expression of GFP, both in the control and bFGF-treated animals (Supplementary Figure 8) . To quantitate the reduction in tumor size following FGF treatment, we counted the number of sections in which tumor cells could be found. As shown in Figure 5h , FGF treatment resulted in a significant reduction in tumor bulk. Based on these results, we conclude that FGF is a potent inhibitor of tumor growth and may be useful for targeting ptc þ / À mutant medulloblastomas and other hedgehog-dependent tumors.
The studies described above reinforce our previous observations that bFGF can inhibit Shh signaling and Shh-induced proliferation in GNPs and tumor cells. Moreover, they provide new insight into mechanisms of bFGF-mediated inhibition, demonstrating that (1) this requires signaling through FGFR1 and (2) that it acts on the Shh pathway at a level downstream of Smo and Sufu. Interestingly, a recent report 51 demonstrates that oncogenic Ras can also inhibit Shh signaling, and that this involves activation of the DYRK1B kinase. As bFGF signaling is likely to involve activation of Ras, it is tempting to speculate that bFGF-mediated inhibition involves a similar mechanism. However, it is notable that oncogenic Ras and Dyrk1B did not affect signaling in Sufu À / À cells, suggesting that the mechanisms underlying inhibition, although they might overlap with those associated with bFGF, are likely distinct.
Notwithstanding the potent inhibitory effects of bFGF in vitro, our studies demonstrate that FGF signaling is not required for normal GNP development. The fact that mice lacking FGF receptors showed no obvious phenotype is surprising, given the marked anti-mitogenic effects of FGF signaling for these cells in vitro. One possible explanation for this is that some level of FGF signaling persists even in the absence of FGF receptors. FGFs are known to activate transcription of Sprouty genes, which function as negative regulators of signaling by FGFRs and other receptor tyrosine kinases. 52 In the absence of FGF signaling, this negative feedback loop could be lost, resulting in a compensatory increase in activation of the FGF pathway. Alternatively, it is possible that other extracellular signals may act independently to promote cell cycle exit and differentiation of GNPs in the postnatal cerebellum. In this regard, it is worth noting that in addition to bFGF, vitronectin, pituitary adenylate cyclase-activating polypeptide and bone morphogenetic proteins 2 and 4 have all been reported to inhibit Shh-induced proliferation of GNPs in vitro. 47, 48, 53, 54 To date, none of these have been shown to be required for GNP differentiation in vivo. Thus, the signals responsible for GNP cell cycle exit and differentiation remain unclear, and the possibility that multiple factors cooperate to regulate these processes remains open.
Whatever its role in GNP development, our studies clearly indicate that FGF signaling can inhibit the growth of GNP-derived tumors. This is significant for several reasons. First, it highlights the unique characteristics of the tumor-propagating cells (cancer stem cells) in these tumors. In contrast to the stem-like (CD133 þ , multipotent and neurosphere-forming) cells that have been shown to be important for propagation of other brain tumors, 55, 56 we have found that growth of ptc-associated medulloblastoma is dependent on GNP-like cells that express the surface marker CD15. 49 Although a recent report suggested that long-term culture of ptc þ / À tumor cells in FGF-containing media can expand a rare population of stem-like cells with tumorigenic potential, 57 our demonstration that acute bFGF treatment-either in vitro or in vivo-dramatically inhibits subsequent tumor growth raises questions about the role of these cells in tumor maintenance and their importance as targets for therapy. Although bFGF is likely to have different effects on different classes of brain tumors (and could potentially enhance the growth of some tumor subtypes), at least for Hedgehog pathway-associated medulloblastoma, it appears to be a potent inhibitor of tumor growth.
Hedgehog antagonists have recently moved into clinical trials for a variety of types of cancer, and have begun to show some promise for treatment of medulloblastoma. 58 However, early reports also suggest that resistance to these antagonists can develop quite readily. 59 Therefore, it is critical to develop alternative approaches to targeting these diseases. Although bFGF does not readily cross the blood-brain barrier, 60 our results suggest that intratumoral injection (perhaps aided by convection-enhanced delivery 61 ) could be an effective mode of therapy. Small molecules that mimic the effects of bFGF [62] [63] [64] might also be useful for overcoming the blood brain barrier. The fact that some medulloblastoma cell lines are growth-inhibited by bFGF 65, 66 suggests that our results are not confined to mouse models, and would be worth pursuing in the context of human medulloblastoma.
MATERIALS AND METHODS Animals
Math1-Cre transgenics 5, 6 were from David Rowitch at UCSF. FGFR1 conditional knockout (Fgfr1 
67
) were maintained on a C57/BL6 background in our colony. NeuroD2-SmoA1 transgenic mice 32 were a gift from James Olson, Fred Hutchinson Cancer Center. FGFR TKO mice were offspring of Fgfr1 24 were bred in our colony. Animals were bred and maintained in the Cancer Center Isolation Facility at Duke Medical Center.
Growth factors bFGF (Peprotech, Rocky Hill, NJ, USA) was used at 25 ng/ml except where indicated. Shh supernatant was generated by transfecting 293T cells with Shh-N expression plasmid (David Robbins, Dartmouth Medical School, Hanover, NH, USA) and harvesting supernatant for 3 days. Supernatant was used at 20% final concentration.
Isolation and culture of GNPs and tumor cells
GNPs were isolated from 2-to 11-day-old mice as described in ref. 50 . Tumor cells were isolated using a similar procedure from ptc þ / À and NeuroD2-SmoA1 mice displaying signs of medulloblastoma. For isolation of CD15 þ and CD15-populations, tumor cells were stained with anti-CD15 antibodies (clone MMA, BD Biosciences, San Jose, CA, USA) and with phycoerythrin-conjugated goat-anti-mouse IgM secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA), and then sorted using a BD FACSVantage flow cytometer. Cells were cultured on poly-D-lysine-coated plates in Neurobasal medium containing 2% B27, 1 mM sodium pyruvate, 2 mM l-glutamine, and 1% Pen/Strep (all from Invitrogen, Carlsbad, CA, USA).
RNA isolation and RT-PCR
RNA was isolated by using the RNAqueous kit (Ambion, Austin, TX, USA). Lysates were treated with DNA-free DNase treatment and removal reagents (Ambion), and RNA was quantitated on a TD-700 fluorometer (Turner BioSystems, Sunnyvale, CA, USA) by using RiboGreen (Invitrogen). RT-PCR for fgfr1-4 was performed using primers described in ref. 34 . First-strand cDNA was synthesized using equivalent amounts of total RNA (0.1-1 mg) in a 20-ml reverse transcriptase reaction mixture (Invitrogen). PCR was performed using Platinium Taq (Invitrogen) in a 25-ml reaction volume followed by electrophoresis on a 1.5% agarose gel. Real-time PCR for gli1 was performed as described in ref. 51 . Sufu À / À MEFs were a generous gift from Matthias Lauth and Rune Toftgard at the Karolinska Institute, Huddinge, Sweden.
Western blotting
GNPs from P7 WT and FGFR TKO mice were cultured for 4 h on poly-Dlysine-coated plates in Neurobasal media with no additives or with 25 ng/ml bFGF. Cells were washed twice with cold PBS and lysed in 200 ml RIPA buffer (0.5 M Tris-HCl, pH 7.4, 1.5 M NaCl, 2.5% deoxycholic acid, 10% NP-40 and 10 mM EDTA) with protease and phosphatase inhibitor cocktail (Thermo, Rockford, IL, USA, Cat no. 1861280) for 30 min on ice. Lysates were sonicated using an ultrasonicator (Misonix, Farmingdale, NY, USA) at amplitude 2 for 5 s, and then centrifuged at 13 000 r.p.m. for 10 min at 4 1C. Protein concentrations were measured using a Bradford assay. Equal amounts of protein were separated by 8% SDS polyacylamide gel electrophoresis and transferred to nitrocellulose membranes (Invitrogen, Cat no. LC2006). Membranes were blocked with 5% bovine serum albumin and then probed with anti-pERK and anti-total ERK (both from Santa Cruz Biotechnology, Santa Cruz, CA, USA), and with IRDye680-labeled Goat antiMouse IgG antibodies (Li-Cor Biosciences, Lincoln, NE, USA). All antibodies were diluted 1:3000 in Tris-buffered saline with 0.1% Tween-20. Proteins were visualized using Li-Cor Odyssey Imager.
Proliferation assays
For measurement of thymidine incorporation, GNPs and tumor cells were cultured in poly-D-lysine-coated 96-well plates at 2 Â 10 5 cells per well. Growth factors were added at the beginning of culture, and cells were incubated for 48 h before being pulsed with (methyl-3H)-Thymidine (PerkinElmer, Fremont, CA, USA). After 16 h, cells were harvested by using a Mach IIIM Manual Harvester 96 (Tomtec, Hamden, CT, USA), and incorporated radioactivity was quantitated by using a Wallac MicroBeta microplate scintillation counter (PerkinElmer).
For cell cycle analysis, cells were cultured in poly-D-lysine-coated plates as described above. After 48 h, cells were fixed and permeabilized for 20 min in 100 ml of BD Cytofix/Cytoperm Solution (BD Biosciences). Cells were then washed with 1 ml of BD Perm/Wash Buffer (BD Biosciences) and resuspended in 20 ml of 7-aminoactinomycin D (7-AAD). Three hundred microliter of FACS buffer (5% fetal bovine serum in PBS) was added to the cells, and samples were analyzed on a FACScan Flow Cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Cell cycle profiles were analyzed using FlowJo software (TreeStar Inc., Ashland, OR, USA).
Immunofluorescence staining and analysis
For staining of frozen tissue, brains were fixed in 4% paraformaldehyde, cryoprotected in 30% sucrose, embedded in Tissue-Tek Optimal Cutting Temperature (OCT) (Sakura Finetek, Torrance, CA, USA) and sectioned sagittally at a thickness of 12 mm. Sections were permeabilized with PBST (PBS þ 0.1% Triton Â -100), blocked with PBST þ 10% normal goat serum, and incubated with primary antibodies specific for Ki67 (Abcam, Cambridge, MA, USA) and NeuN (Millipore, Temecula, CA, USA) overnight at 4 1C followed by Alexa Fluor 594-anti-rabbit and Alexa Fluor 488-anti-mouse secondary antibodies (Molecular Probes, Eugene, OR, USA) for 1 h at room temperature. Sections were counterstained with DAPI (4'-6-diamidino-2-phenylindole) (Molecular Probes) and mounted in Fluoromount-G (Southern Biotechnology Associates, Birmingham, AL, USA). Tiled images were taken using a Zeiss LSM 510 inverted confocal microscope and related software at the Duke Light Microscopy Core Facility.
To measure apoptosis, GNPs or tumor cells were fixed in 4% paraformaldehyde and stained with antibodies against cleaved caspase-3 (Cell Signaling Technology, Danvers, MA, USA) and goat anti-rabbit IgG secondary antibodies (Jackson ImmunoResearch). Following staining, immunofluorescent pictures of six randomly-selected fields were taken from each well of cultured cells using a Zeiss LSM 510 inverted confocal microscope and related software at the Duke Light Microscopy Core Facility. Cells were counted for positive cleaved caspase-3 and DAPI, respectively. The ratio of cleaved caspase-3 to DAPI staining was determined for each culture condition and compared.
Stereotaxic implantation and in vivo treatment of tumor cells
Tumor cells from Math1-GFP; ptc þ / À mice were transplanted into SCIDbeige mice as described in ref. 49 . For bFGF pretreatment studies, animals FGF inhibits growth of hedgehog-associated medulloblastoma BA Emmenegger et al were followed for 6 months and killed when they developed symptoms of medulloblastoma (ataxia, lethargy and hydrocephaly). For in vivo bFGF treatment studies, PBS or bFGF (80 ng/ml, 2.5 ml) was injected into the transplant site 8-12 days after transplantation, and again 3-5 days later. When any of the mice in a cohort exhibited symptoms, the entire cohort was killed. Animals were perfused with 4% paraformaldehyde and brains were imaged by whole mount microscopy using a Leica MC 16 FA microscope, Micropublisher 5.0 RTV camera and QCapture software (QImaging, Surray, BC, Canada). Brains were then frozen in OCT, sectioned from end to end, and stained with hematoxylin and eosin or with DAPI as described above. Sections were examined for the presence of GFP þ tumor cells, and lateral tumor extension was calculated by counting the number of sections containing such cells and multiplying by the thickness of these sections.
